Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration

Neurobiology of Disease

Volumn 71, Issue 1, 2014, Pages 345-358

  Tsika, Elpida ^a   Kannan, Meghna ^a   Foo, Caroline Shi Yan ^a   Dikeman, Dustin ^a,b   Glauser, Liliane ^a   Gellhaar, Sandra ^c   Galter, Dagmar ^c   Knott, Graham W ^a   Dawson, Ted M ^b,d   Dawson, Valina L ^b,d   Moore, Darren J ^a,e  

^a EPFL   (Switzerland)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d ADRIENNE HELIS MALVIN MEDICAL RESEARCH FOUNDATION   (United States)

^e VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Dopaminergic; LRRK2; Neurodegeneration; Nuclear envelope; PARK8; Parkinson's disease; Transgenic

Indexed keywords

ALPHA SYNUCLEIN; ARGININE; BIOLOGICAL MARKER; CYSTEINE; DOPAMINE; LEUCINE RICH REPEAT KINASE 2; PROTEIN P62; TAU PROTEIN; UBIQUITIN; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

AGING; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CELL NUCLEUS; CELL NUCLEUS MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; LRRK2 GENE; MALE; MOTOR ACTIVITY; MOUSE; NEURITE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SMELLING; SUBSTANTIA NIGRA; ANIMAL; CELL CULTURE; CYTOLOGY; GENETICS; HUMAN; MESENCEPHALON; MUTATION; NUCLEOLUS; PATHOLOGY; TRANSGENIC MOUSE; ULTRASTRUCTURE;

ANIMALS; ARGININE; CELL NUCLEOLUS; CELLS, CULTURED; CYSTEINE; DOPAMINERGIC NEURONS; HUMANS; MESENCEPHALON; MICE; MICE, TRANSGENIC; MUTATION; PROTEIN-SERINE-THREONINE KINASES;

EID: 84949117317     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.08.027     Document Type: Article

References (65)

1. Biosa A., Trancikova A., Civiero L., Glauser L., Bubacco L., Greggio E., Moore D.J. GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2. Hum. Mol. Genet. 2013, 22:1140-1156.
2. Biskup S., West A.B. Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochim. Biophys. Acta 2009, 7:625-633.
3. Biskup S., Moore D.J., Celsi F., Higashi S., West A.B., Andrabi S.A., Kurkinen K., Yu S.W., Savitt J.M., Waldvogel H.J., et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol. 2006, 60:557-569.
4. Chen C.Y., Weng Y.H., Chien K.Y., Lin K.J., Yeh T.H., Cheng Y.P., Lu C.S., Wang H.L. (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD. Cell Death Differ. 2012, 19:1623-1633.
5. Daher J.P., Ying M., Banerjee R., McDonald R.S., Hahn M.D., Yang L., Flint Beal M., Thomas B., Dawson V.L., Dawson T.M., et al. Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons. Mol. Neurodegener. 2009, 4:34.
6. Daher J.P., Pletnikova O., Biskup S., Musso A., Gellhaar S., Galter D., Troncoso J.C., Lee M.K., Dawson T.M., Dawson V.L., et al. Neurodegenerative phenotypes in an A53T alpha-synuclein transgenic mouse model are independent of LRRK2. Hum. Mol. Genet. 2012, 21:2420-2431.
7. D'Angelo M.A., Raices M., Panowski S.H., Hetzer M.W. Age-dependent deterioration of nuclear pore complexes causes a loss of nuclear integrity in postmitotic cells. Cell 2009, 136:284-295.
8. Funayama M., Hasegawa K., Ohta E., Kawashima N., Komiyama M., Kowa H., Tsuji S., Obata F. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann. Neurol. 2005, 57:918-921.
9. Gasser T. Mendelian forms of Parkinson's disease. Biochim. Biophys. Acta 2009, 7:587-596.
10. Giasson B.I., Covy J.P., Bonini N.M., Hurtig H.I., Farrer M.J., Trojanowski J.Q., Van Deerlin V.M. Biochemical and pathological characterization of Lrrk2. Ann. Neurol. 2006, 59:315-322.
11. Gilks W.P., Abou-Sleiman P.M., Gandhi S., Jain S., Singleton A., Lees A.J., Shaw K., Bhatia K.P., Bonifati V., Quinn N.P., et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005, 365:415-416.
12. Gillardon F., Schmid R., Draheim H. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience 2012, 208:41-48.
13. Greggio E., Cookson M.R. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 2009, 1.
14. Greggio E., Jain S., Kingsbury A., Bandopadhyay R., Lewis P., Kaganovich A., van der Brug M.P., Beilina A., Blackinton J., Thomas K.J., et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 2006, 23:329-341.
15. Gu X., Andre V.M., Cepeda C., Li S.H., Li X.J., Levine M.S., Yang X.W. Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease. Mol. Neurodegener. 2007, 2:8.
16. Healy D.G., Falchi M., O'Sullivan S.S., Bonifati V., Durr A., Bressman S., Brice A., Aasly J., Zabetian C.P., Goldwurm S., et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 2008, 7:583-590.
17. Herzig M.C., Bidinosti M., Schweizer T., Hafner T., Stemmelen C., Weiss A., Danner S., Vidotto N., Stauffer D., Barske C., et al. High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain. PLoS One 2012, 7:15.
18. Higashi S., Moore D.J., Colebrooke R.E., Biskup S., Dawson V.L., Arai H., Dawson T.M., Emson P.C. Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. J. Neurochem. 2007, 100:368-381.
19. Hulihan M.M., Ishihara-Paul L., Kachergus J., Warren L., Amouri R., Elango R., Prinjha R.K., Upmanyu R., KefiM., Zouari M., et al. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study. Lancet Neurol. 2008, 7:591-594.
20. International Parkinson Disease Genomics C., Nalls M.A., Plagnol V., Hernandez D.G., Sharma M., Sheerin U.M., Saad M., Simon-Sanchez J., Schulte C., Lesage S., et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011, 377:641-649.
21. Kim B., Yang M.S., Choi D., Kim J.H., Kim H.S., Seol W., Choi S., Jou I., Kim E.Y., Joe E.H. Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. PLoS One 2012, 7:e34693.
22. Lang A.E., Lozano A.M. Parkinson's disease. First of two parts. N. Engl. J. Med. 1998, 339:1044-1053.
23. Lang A.E., Lozano A.M. Parkinson's disease. Second of two parts. N. Engl. J. Med. 1998, 339:1130-1143.
24. Lesage S., Durr A., Tazir M., Lohmann E., Leutenegger A.L., Janin S., Pollak P., Brice A., French Parkinson's Disease Genetics Study G. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N. Engl. J. Med. 2006, 354:422-423.
25. Li Y., Liu W., Oo T.F., Wang L., Tang Y., Jackson-Lewis V., Zhou C., Geghman K., Bogdanov M., Przedborski S., et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat. Neurosci. 2009, 12:826-828.
26. Li X., Patel J.C., Wang J., Avshalumov M.V., Nicholson C., Buxbaum J.D., Elder G.A., Rice M.E., Yue Z. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J. Neurosci. 2010, 30:1788-1797.
27. Lin X., Parisiadou L., Gu X.L., Wang L., Shim H., Sun L., Xie C., Long C.X., Yang W.J., Ding J., et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 2009, 64:807-827.
28. Liu G.H., Qu J., Suzuki K., Nivet E., Li M., Montserrat N., Yi F., Xu X., Ruiz S., Zhang W., et al. Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature 2012, 491:603-607.
29. MacLeod D., Dowman J., Hammond R., Leete T., Inoue K., Abeliovich A. The familial parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 2006, 52:587-593.
30. Maekawa T., Mori S., Sasaki Y., Miyajima T., Azuma S., Ohta E., Obata F. The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities. Mol. Neurodegener. 2012, 7:1326-1750.
31. Melrose H.L., Dachsel J.C., Behrouz B., Lincoln S.J., Yue M., Hinkle K.M., Kent C.B., Korvatska E., Taylor J.P., Witten L., et al. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol. Dis. 2010, 40:503-517.
32. Moehle M.S., Webber P.J., Tse T., Sukar N., Standaert D.G., DeSilva T.M., Cowell R.M., West A.B. LRRK2 inhibition attenuates microglial inflammatory responses. J. Neurosci. 2012, 32:1602-1611.
33. Nichols W.C., Pankratz N., Hernandez D., Paisan-Ruiz C., Jain S., Halter C.A., Michaels V.E., Reed T., Rudolph A., Shults C.W., et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 2005, 365:410-412.
34. Ozelius L.J., Senthil G., Saunders-Pullman R., Ohmann E., Deligtisch A., Tagliati M., Hunt A.L., Klein C., Henick B., Hailpern S.M., et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 2006, 354:424-425.
35. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., Lopez de Munain A., Aparicio S., Gil A.M., Khan N., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004, 44:595-600.
36. Parisiadou L., Xie C., Cho H.J., Lin X., Gu X.L., Long C.X., Lobbestael E., Baekelandt V., Taymans J.M., Sun L., et al. Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J. Neurosci. 2009, 29:13971-13980.
37. Plowey E.D., Cherra S.J., Liu Y.J., Chu C.T. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J. Neurochem. 2008, 105:1048-1056.
38. Rajput A., Dickson D.W., Robinson C.A., Ross O.A., Dachsel J.C., Lincoln S.J., Cobb S.A., Rajput M.L., Farrer M.J. Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 2006, 67:1506-1508.
39. Ramonet D., Daher J.P., Lin B.M., Stafa K., Kim J., Banerjee R., Westerlund M., Pletnikova O., Glauser L., Yang L., et al. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One 2011, 6:0018568.
40. Ramonet D., Podhajska A., Stafa K., Sonnay S., Trancikova A., Tsika E., Pletnikova O., Troncoso J.C., Glauser L., Moore D.J. PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity. Hum. Mol. Genet. 2012, 21:1725-1743.
41. Ramsden N., Perrin J., Ren Z., Lee B.D., Zinn N., Dawson V.L., Tam D., Bova M., Lang M., Drewes G., et al. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem. Biol. 2011, 6:1021-1028.
42. Rodriguez S., Eriksson M. Evidence for the involvement of lamins in aging. Curr. Aging Sci. 2010, 3:81-89.
43. Ross O.A., Toft M., Whittle A.J., Johnson J.L., Papapetropoulos S., Mash D.C., Litvan I., Gordon M.F., Wszolek Z.K., Farrer M.J., et al. Lrrk2 and Lewy body disease. Ann. Neurol. 2006, 59:388-393.
44. Satake W., Nakabayashi Y., Mizuta I., Hirota Y., Ito C., Kubo M., Kawaguchi T., Tsunoda T., Watanabe M., Takeda A., et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 2009, 41:1303-1307.
45. Scaffidi P., Misteli T. Lamin A-dependent nuclear defects in human aging. Science 2006, 312:1059-1063.
46. Simon-Sanchez J., Schulte C., Bras J.M., Sharma M., Gibbs J.R., Berg D., Paisan-Ruiz C., Lichtner P., Scholz S.W., Hernandez D.G., et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 2009, 41:1308-1312.
47. Smith W.W., Pei Z., Jiang H., Moore D.J., Liang Y., West A.B., Dawson V.L., Dawson T.M., Ross C.A. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18676-18681.
48. Smith W.W., Pei Z., Jiang H., Dawson V.L., Dawson T.M., Ross C.A. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 2006, 9:1231-1233.
49. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat. Genet. 1999, 21:70-71.
50. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
51. Srinivas S., Watanabe T., Lin C.S., William C.M., Tanabe Y., Jessell T.M., Costantini F. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev. Biol. 2001, 1:4.
52. Stafa K., Trancikova A., Webber P.J., Glauser L., West A.B., Moore D.J. GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genet. 2012, 8:9.
53. Tong Y., Pisani A., Martella G., Karouani M., Yamaguchi H., Pothos E.N., Shen J. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14622-14627.
54. Tsika E., Moore D.J. Mechanisms of LRRK2-mediated neurodegeneration. Curr. Neurol. Neurosci. Rep. 2012, 12:251-260.
55. Tsika E., Moore D.J. Contribution of GTPase activity to LRRK2-associated Parkinson disease. Small GTPases 2013, 4.
56. Turiault M., Parnaudeau S., Milet A., Parlato R., Rouzeau J.D., Lazar M., Tronche F. Analysis of dopamine transporter gene expression pattern - generation of DAT-iCre transgenic mice. FEBS J. 2007, 274:3568-3577.
57. West A.B., Moore D.J., Choi C., Andrabi S.A., Li X., Dikeman D., Biskup S., Zhang Z., Lim K.L., Dawson V.L., et al. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 2007, 16:223-232.
58. West A.B., Cowell R.M., Daher J.P., Moehle M.S., Hinkle K.M., Melrose H.L., Standaert D.G., Volpicelli-Daley L.A. Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents. J. Comp. Neurol. 2014, 522:2465-2480.
59. Worman H.J., Ostlund C., Wang Y. Diseases of the nuclear envelope. Cold Spring Harb. Perspect. Biol. 2010, 2:a000760.
60. Woulfe J.M. Abnormalities of the nucleus and nuclear inclusions in neurodegenerative disease: a work in progress. Neuropathol. Appl. Neurobiol. 2007, 33:2-42.
61. Xiong Y., Coombes C.E., Kilaru A., Li X., Gitler A.D., Bowers W.J., Dawson V.L., Dawson T.M., Moore D.J. GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet. 2010, 6:1000902.
62. Yang M., Crawley J.N. Simple Behavioral Assessment of Mouse Olfaction. Current Protocols in Neuroscience/Editorial Board, Jacqueline N. Crawley. [et al.] 2009, (Chapter 8, Unit 8 24).
63. Zhou H., Huang C., Tong J., Hong W.C., Liu Y.J., Xia X.G. Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. Int. J. Biol. Sci. 2011, 7:753-761.
64. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.
65. Zimprich A., Muller-Myhsok B., Farrer M., Leitner P., Sharma M., Hulihan M., Lockhart P., Strongosky A., Kachergus J., Calne D.B., et al. The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am. J. Hum. Genet. 2004, 74:11-19.